claim: cold-adapted live attenuated sars-cov-2 vaccine completely challenged human ace2 transgenic mice from sars-cov-2 infection
evidence_1: view full-text keywords: sars-cov-2; live attenuated vaccine; cold adaptation sars-cov-2; live attenuated vaccine; cold adaptation  show figures figure 1 this is an open access article distributed under the creative commons attribution license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited ", "the one-dose vaccinated mice were completely protected from sars-cov-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal iga antibodies in intranasally immunised k18-hace2 mice, which are very susceptible to sars-cov-2 and sars-cov infections.", "these results demonstrate that the cold-adapted live attenuated sars-cov-2 vaccine we have developed may be a candidate sars-cov-2 vaccine for humans.")